Cronos (TSX:CRON) Shares Tank, But is it Now a Buy?

There’s a lot happening at Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON), but does that make the cheap share price a buy?

| More on:

After some good news finally coming out of the cannabis industry, it looked like marijuana producer Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) would be the latest to hitch a ride on that train.

In fact, the stock did see some significant improvement when it released its second quarterly report. Net revenue tripled from the same time last year to $10.2 million. Even more impressive, the company joined the limited ranks of marijuana producers finally posting a profit, with Cronos reporting $251 million in profit for the quarter.

But this is where things get tricky, as the devil is in the details. While a profit is impressive, it looks like it could be a one-off. Cronos received a $263.9 million gain from a revaluing of its warrants. It looks like investors may have caught on, because the stock is still down despite the good news. The stock jumped about 8% after the report came out, reaching as high as $19.18 per share before dropping back down by almost 10% to about $17.50, where it is now.

So let’s look at whether Cronos has what it takes to deserve your money.

Asset strategy

The main fuel behind Cronos’ growth right now is through acquisitions. The company has been snapping up companies left, right and centre to further its growth initiative, providing the ability to expand into a number of spaces related to cannabis. Some of its recent acquisitions include Lord Jones, a cannabidiol (CBD) beauty brand that’s already popular in the United States, giving the company access to the U.S. market.

Another recent acquisition is through Ginkgo Bioworks last year, a company that focuses on biosynthesis, an area that Cronos is extremely interested in. Biosynthesis could provide an incredibly cheap way of cultivating cannabis. While the initial price tag will likely be high, biosynthesis allows a company like Cronos to create biologically identical CBD compared to the marijuana plant. The process can be done on a large scale, so once it’s up and running this could be a huge win for Cronos.

Heading South

The acquisition of Lord Jones was a great first step, but Cronos had an even better move come out August 2 when it announced it would be acquiring Redwood Holding Group. The company manufactures and markets hemp-derived CBD, all in the United States. This acquisition should significantly add to the company’s revenue stream, especially with its biosynthesis project in the works.

But while the company seems rather focused on CBD, it looks like research into cannabis as a whole might be left to the wayside. This is where the money lies, especially in the medical space. While its projects should increase its revenue south of the border, it might be harder for Cronos to expand into other areas besides CBD, especially since so many of its peers are already setting up the process to do so. Basically, the derivatives market likely won’t be enough to put this company on top.

Production lag

The main problem I have with Cronos is that the company is simply far behind its peers when it comes to production. Even though the company has increased its kilograms sold, it’s still substantially behind. The company recently reported 1,584 kilograms sold in its recent report, compared to heavyweight Aurora Cannabis that predicts it will sell on the top-end of between 25,000 and 30,000 kilograms.

If we continue the comparison, Aurora has a market cap of $8.23 billion compared to Cronos’ $5.89 billion. Those numbers are similar enough that Cronos should be making much heavier moves than it is. Aurora is in the most countries of its peers at 24, and is set to produce the most amount of pot come June 2020. Cronos, meanwhile, has just entered the U.S.  Instead, the company is making expensive acquisitions that may not pay off compared to simple production growth.

Foolish takeaway

I agree with analysts that this stock is at best a hold, and should perform neutral amongst its peers in at least the near term. Some of that money coming in from its partnerships needs to be used to strengthen investor confidence. Until that happens, any profits and jumps in revenue are likely only temporary.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe owns shares of Aurora Cannabis Inc. 

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »